Uridine and its role in metabolic diseases, tumors, and neurodegenerative diseases.

O-GlcNAc circadian rhythm diabetes metabolic diseases neurodegenerative diseases obesity uridine

Journal

Frontiers in physiology
ISSN: 1664-042X
Titre abrégé: Front Physiol
Pays: Switzerland
ID NLM: 101549006

Informations de publication

Date de publication:
2024
Historique:
received: 04 01 2024
accepted: 19 02 2024
medline: 15 3 2024
pubmed: 15 3 2024
entrez: 15 3 2024
Statut: epublish

Résumé

Uridine is a pyrimidine nucleoside found in plasma and cerebrospinal fluid with a concentration higher than the other nucleosides. As a simple metabolite, uridine plays a pivotal role in various biological processes. In addition to nucleic acid synthesis, uridine is critical to glycogen synthesis through the formation of uridine diphosphate glucose in which promotes the production of UDP-GlcNAc in the hexosamine biosynthetic pathway and supplies UDP-GlcNAc for O-GlcNAcylation. This process can regulate protein modification and affect its function. Moreover, Uridine has an effect on body temperature and circadian rhythms, which can regulate the metabolic rate and the expression of metabolic genes. Abnormal levels of blood uridine have been found in people with diabetes and obesity, suggesting a link of uridine dysregulation and metabolic disorders. At present, the role of uridine in glucose metabolism and lipid metabolism is controversial, and the mechanism is not clear, but it shows the trend of long-term damage and short-term benefit. Therefore, maintaining uridine homeostasis is essential for maintaining basic functions and normal metabolism. This article summarizes the latest findings about the metabolic effects of uridine and the potential of uridine metabolism as therapeutic target in treatment of metabolic disorders.

Identifiants

pubmed: 38487261
doi: 10.3389/fphys.2024.1360891
pii: 1360891
pmc: PMC10937367
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

1360891

Informations de copyright

Copyright © 2024 Yang, Ye, Deng and Gao.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Yueyuan Yang (Y)

Department of Endocrinology, Renmin Hospital of Wuhan University, Wuhan, China.

Yahong Ye (Y)

Department of Internal Medicine, QuanZhou Women's and Children's Hospital, QuanZhou, China.

Yingfeng Deng (Y)

Department of Diabetes and Cancer Metabolism, City of Hope, Duarte, CA, United States.

Ling Gao (L)

Department of Endocrinology, Renmin Hospital of Wuhan University, Wuhan, China.

Classifications MeSH